FOLR1: Folate receptor alpha
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells.
- Drugs that act on it: 4
- Approved: 1
- In phases 1 to 3: 3
- Sponsors: 3
Who Is On It, and How Far Along
Every drug ChEMBL records acting on FOLR1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody
- Antibody-drug conjugate
- Other
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- AbbVie250%
- CSPC Megalith Biopharmaceutical Co.,Ltd.125%
- Endocyte125%
Modalities
Drugs on this target by ChEMBL molecule type.
- Antibody250%
- Antibody-drug conjugate125%
- Other125%
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 3 of 4 act as: Folate receptor alpha binding agent; the rest name their own mechanism.| Mirvetuximab soravtansine | Approved | AbbVie | Antibody-drug conjugate | Binding agent | — | 21 | Boxed warning |
| Farletuzumab | Phase 3 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Antibody | Inhibitor | Folate receptor alpha inhibitor | 2 | — |
| Vintafolide | Phase 3 | Endocyte | Other | Binding agent | — | 0 | — |
| Mirvetuximab | Phase 2 | AbbVie | Antibody | Binding agent | — | 22 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 11 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Neurodegenerative syndrome due to cerebral folate transport deficiency
- 0.81
- Ovarian cancer
- 0.53
- Neoplasm
- 0.50
- Fallopian tube neoplasm
- 0.46
- Peritoneal neoplasm
- 0.46
- Malignant epithelial tumor of ovary
- 0.45
- Seizure
- 0.41
- Primary peritoneal carcinoma
- 0.39
- Ovarian neoplasm
- 0.38
- Ovarian carcinoma
- 0.37
- Hereditary disease
- 0.34
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2121, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P15328, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets